



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,894	12/02/2005	Karin Klokke	930008-2202 (BOE0003US.NP)	6226
7590 12/05/2007				
Jane Massey Licata, Esquire Licata & Tyrrell P.C. 66 E. Main Street Marlton, NJ 08053		EXAMINER SASAN, ARADHANA		
		ART UNIT	PAPER NUMBER	
		1615		
		MAIL DATE	DELIVERY MODE	
		12/05/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/541,894	Applicant(s) KLOKKERS ET AL.	
	Examiner Aradhana Sasan	Art Unit 1615	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 10 April 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 24-48 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 24-48 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>7/8/05, 12/2/05</u> . | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Status of Application***

1. Claims 1-23 were canceled.
2. Claims 24-48 are included in the prosecution.

### ***Priority***

3. Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d).

### ***Information Disclosure Statement***

4. The information disclosure statements (IDS) submitted on 7/8/05 and 12/2/05 are acknowledged. The submissions are in compliance with the provisions of 37 CFR 1.97 and 1.98. Accordingly, the examiner is considering the information disclosure statements. See attached copy of PTO-1449.

### ***Specification***

5. The use of the following trademarks has been noted in this application:  
COMPRITOL (Pages 9, 11 and 12), CUTINA HR (Page 9), MIGLYOL (Page 9),  
AEROSIL (Pages 11 and 12), KOLLIDON (Pages 11 and 12), TABLETTOSE (Page 11),  
and MICROCELLAC (Page 12). They should be written in all capital letters wherever  
they appear; or alternatively, they should be denoted with the registered trademark  
symbol, ®, and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

***Claim Rejections - 35 USC § 102***

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 24-31, 34-35, 38, 40-43 and 45-48 are rejected under 35 U.S.C. 102(b) as being anticipated by Price et al. (US 4,128,658).

The claimed invention is a method for preparing granules comprising wetting a mixture of active ingredient(s) and retarding agent(s) with an oily substance and granulating the wetted mixture.

Price teaches a method of producing oral sustained release tablets. "The active ingredient, anhydrous lactose and most of the Cutina HR (a hydrogenated castor oil) are intimately mixed and then the mixture is moistened by mixing with a 10% solution of the remainder of the Cutina HR ... the moistened mass is granulated through a 1.2 mm aperture sieve and dried at 50°C in a fluidised bed dryer. The granules are then passed through a 0.85 mm aperture sieve, blended with the magnesium stearate and compressed ... on a tableting machine with 12.5mm diameter punches" (Col. 29, Example c, lines 29-47). In another exemplified preparation (for an oral syrup), the drug is dissolved in water (Col. 29, line 56). Since the drug dissolves in water it is inherently hydrophilic.

Regarding instant claims 24 and 41, the limitations of a method for preparing granules comprising wetting a mixture of one or more active ingredients and one or

Art Unit: 1615

more retarding agents with an oily substance are anticipated by the granulation method of an active ingredient mixed with anhydrous lactose and a hydrogenated castor oil taught by Price (Col. 29, Example c, lines 29-47). The retarding agent is the lipophilic hydrogenated castor oil. The wetting of the mixture is anticipated by the moistening by the hydrogenated castor oil. The granulation step is anticipated by the fluidized bed granulation step taught by Price. The limitation of compressing the granules so that tablets are prepared of instant claim 41 is anticipated by the compression of granules to form tablets as taught by Price.

Regarding instant claim 25, the limitation of the mixture further comprising excipients is anticipated by the excipient anhydrous lactose taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 26, the limitation of wetting the mixture by spraying is anticipated by the fluidized bed spray dryer taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 27, the limitation of wetting the mixture at room temperature is anticipated by method taught by Price (Col. 29, Example c, lines 29-47). Since Price does not disclose a specific temperature for the wetting or moistening step, one skilled in the art can readily envisage that the process is carried out at room temperature.

Regarding instant claim 28, the limitation of a hydrophilic active ingredient is anticipated by the active ingredient that dissolves in water, as taught by Price (Col. 29, line 56). Since the drug dissolves in water it is inherently hydrophilic.

Regarding instant claims 29-30, the limitation of the active ingredient content is anticipated by the 37.5% (1.5Kg/4Kg) of active ingredient as taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 31, the limitation of the lipophilic retarding agent is anticipated by the hydrogenated castor oil taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claims 34-35, the limitations of the oily substance and the percentage of the oily substance are anticipated by the 10% (0.4Kg/4Kg) of CUTINA HR® (hydrogenated castor oil) taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 38, the limitation of the fluidized bed granulator is anticipated by the fluidised bed dryer taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 40, the limitation of compressing the granules into tablets is anticipated by the tablets formed by compressing granules as taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 42, the limitation of mixing the granules with at least one excipient prior to compressing the granules is anticipated by mixing magnesium stearate with the granules before compressing into tablets as taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 43, the limitation of the excipient is anticipated by the lubricant magnesium stearate taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claims 45-48, the limitations of the granules and the tablet are anticipated by the granules and tablet prepared by the method taught by Price (Col. 29, Example c, lines 29-47).

Therefore, the limitations of claims 24-31, 34-35, 38, 40-43 and 45-48 are anticipated by the teachings of Price.

***Claim Rejections - 35 USC § 103***

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. Claims 32-33, 36-37, 39 and 44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Price et al. (US 4,128,658) in view of Santus et al. (US 5,472,704).

The teaching of Price is stated above.

Price does not expressly teach the combination of the lipophilic retarding agent with a hydrogel matrix forming agent or a structural matrix forming agent.

Santus teaches bioadhesive granules with matrix units for the controlled release of furosemide (Col. 8, lines 63-64, Example 1). A hydrophobic matrix is obtained by granulation with melted excipients (Col. 8, lines 66-67). "50 parts of furosemide are mixed with 25 parts of hydrogenated castor oil and the resulting mixture is kneaded using 25 parts of melted hydrogenated castor oil as a granulation fluid. The resulting mixture is granulated ... the granules are mixed with ... an acrylic copolymer and ... hydroxypropylmethylcellulose ... the mixture is then tableted in an eccentric press ...

Art Unit: 1615

obtaining tablets with a diameter of 21mm. The tablets are then crumbled and sieved so as to obtain granules ..." (Col. 9, lines 1-12). A fluid bed system (WURBTER-GLATT®) is disclosed (Col. 8, lines 58-59). Excipients that are commonly known in the art are disclosed (Col. 7, lines 1-5).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the method of producing granules with an active ingredient and a lipophilic retarding agent, as suggested by Price, combine it with the method of producing granules of active ingredients with a lipophilic retarding agent in combination with acrylic copolymer and hydroxypropylmethylcellulose, as taught by Santus, and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because Santus teaches that cellulose derivatives such as hydroxypropylmethylcellulose (HPMC) are bioadhesive polymers. One skilled in the art would know that bioadhesive polymers are crucial for extended release formulations and would include it for extending the release of hydrophilic active ingredients.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Regarding instant claims 32-33, the limitations of the structural matrix forming agent and hydrogel matrix forming agent would have been obvious to one skilled in the



Art Unit: 1615

art over the HPMC taught by Santus (Col. 9, lines 1-12). The limitation of the water soluble excipients would have been obvious over the anhydrous lactose taught by Price (Col. 29, Example c, lines 29-47).

Regarding instant claim 36, the percentage range of the oily substance would have been obvious over the 10% (0.4Kg/4Kg) of CUTINA HR® (hydrogenated castor oil) taught by Price (Col. 29, Example c, lines 29-47). One skilled in the art would modify the level of the oily substance during the process of routine experimentation in order to optimize the sustained or extended release attributes and the stability of the resultant granules.

Regarding instant claim 37, the limitation of the granules further comprising an outer phase of one or more retarding agents would have been obvious over the microunit coating taught by Santus. The method disclosed can coat individual microunits (Col. 8, lines 36-40).

Regarding instant claim 39, the limitation of the granule binder would have been obvious over the HPMC taught by Santus (Col. 9, lines 1-12).


Regarding instant claim 44, the limitation of the tablet further comprising a coating would have been obvious over the tablets taught by Price (Col. 29, Example c, lines 29-47) and because one skilled in the art would employ tablet coatings during the process of routine optimization in order to enhance the stability and shelf-life of the tablet, to mask the off-notes, and to provide a layer of sustained release coating for extending the therapeutic effect of the chosen active ingredient.

***Conclusion***

10. No claims are allowed.
11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Aradhana Sasan whose telephone number is (571) 272-9022. The examiner can normally be reached Monday to Thursday from 6:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached at 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
MICHAEL P. WOODWARD  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600